INVA is the ticker symbol for Innoviva, Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks INVA with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is INVA a good stock to buy?

13F Pro's AI ranking engine scores INVA at 70.9/100, ranked #196 of 2,925 stocks on a composite quality score built from its SEC filings, covering profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for INVA is available at https://13fpro.ai/company/INVA. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source INVA data?

All Innoviva, Inc. fundamentals and ownership data come directly from SEC EDGAR. Innoviva, Inc. files with the SEC under CIK 1080014. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Innoviva, Inc. INVA

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #196 of 2,925TOP 10%

Why it scores 71 Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$119.59M

Quarter to Jun 30

Net income

$-83.42M

Quarter to Jun 30

Free cash flow

$51.54M

Quarter to Jun 30

Operating margin

42.5%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026

$1.94B total

BlackRock, Inc.

$267.96M+9.1%

DIMENSIONAL FUND ADVISORS LP

$102.06M+1.3%

VANGUARD PORTFOLIO MANAGEMENT LLC

$95.84M-0.1%

RENAISSANCE TECHNOLOGIES LLC

$91.67M-0.5%

STATE STREET CORP

$74.22M+6.8%

VANGUARD CAPITAL MANAGEMENT LLC

$71.72M+0.5%

MILLENNIUM MANAGEMENT LLC

$57.71M+11.5%

CAMDEN ASSET MANAGEMENT L P /CA

$52.53M+19.5%

GEODE CAPITAL MANAGEMENT, LLC

$47.13M+7.5%

WOLVERINE ASSET MANAGEMENT LLC

$46.34M+31.9%

SYSTEMATIC FINANCIAL MANAGEMENT LP

$45.96M0.0%

Boston Partners

$43.78M+12.2%

CITADEL ADVISORS LLC

$42.95M+93.8%

Sarissa Capital Management LP

$42.94M-11.3%

BANK OF AMERICA CORP /DE/

$37.87M+2.9%

GOLDMAN SACHS GROUP INC

$36.79M+1.7%

AMERICAN CENTURY COMPANIES INC

$34.02M-21.6%

MARSHALL WACE, LLP

$33.03M-3.3%

MORGAN STANLEY

$27.73M-6.9%

ROYCE & ASSOCIATES LP

$26.63M+10.5%

CHARLES SCHWAB INVESTMENT MANAGEMENT INC

$26.15M-1.1%

Point72 Asset Management, L.P.

$25.88M+26.2%

TWO SIGMA INVESTMENTS, LP

$23.46M-92.9%

CAPSTONE INVESTMENT ADVISORS, LLC

$22.59M0.0%

Qube Research & Technologies Ltd

$22.12M+23.9%

See all 323 institutional holders →

What's Driving INVA's Business? Latest 10-Q Breakdown

36/36 datapoints verified

AI-extracted from the 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Total revenue grew 19% YoY to $119.6M as net product sales surged 46%, but a net loss of $83.4M resulted from a $131.8M unrealized loss on the Armata equity stake.

Biggest Revenue Drivers

Royalty revenue, net$56.3M-12% YoY

Decrease driven by lower net sales due to pricing pressures in the United States

Net product sales$51.8M+46% YoY

Higher sales volume from strategic commercialization efforts, led by XACDURO and GIAPREZA growth

Biggest Revenue Drivers

Total revenue: $119.6M+19% YoY

Royalty revenue, net$56.3M-12% YoY

Decrease driven by lower net sales due to pricing pressures in the United States

Net product sales$51.8M+46% YoY

Higher sales volume from strategic commercialization efforts, led by XACDURO and GIAPREZA growth

Within Net product sales

XACDURO$22.4M+109% YoY

Includes ex-U.S. sales under interim supply agreement with Zai Lab billed at cost

GIAPREZA$22.3M+29% YoY

License and other revenue$11.5M+$10.6M YoY

Derived primarily from arrangements with Zai Lab and new agreements with GARDP and Dr. Reddy's Laboratories

Largest Expense Items

Selling, general and administrative$34.6M+31% YoY

Expanded sales force to meet demand in new regions, promote marketed critical care products and support administrative functions

Cost of products sold$22.3M+111% YoY

Increase driven by higher product sales volume

Amortization of acquired intangible assets$6.6M+1% YoY

Research and development$5.2M-35% YoY

Lower external services costs, partially offset by personnel and facilities costs supporting acquired IPR&D

Margins: Gross profit rose to $90.6M from $83.1M YoY despite cost of products sold more than doubling, as product sales growth outpaced cost increases; income from operations grew modestly to $50.9M reflecting operating discipline.

Watch Items from the Filing

Three customers accounted for 25%, 21%, and 21% of net product sales for the quarter, and 30%, 28%, and 15% of related receivables as of June 30, 2026.
Net loss of $83.4M driven by a $131.8M unrealized loss on the Armata equity method investment due to a lower share price.
Majority of revenues derive from GSK royalty payments; near-term success depends on GSK's commercialization performance for RELVAR/BREO and ANORO.
Company repurchased $31.4M of stock in Q2 2026 ($56.4M since program inception) under its $125M authorization, signaling management confidence.
RELVAR/BREO royalty revenue declined 13% YoY to $47.7M, its largest revenue line, due to U.S. pricing pressure.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →

Key Metrics

Revenue

Q2 2026

EDGAR

Net Income

Q2 2026

EDGAR

EPS (Diluted)

Q2 2026

EDGAR

Operating Margin

Q2 2026

EDGAR

ROIC

Q2 2026

EDGAR

Free Cash Flow

Q2 2026

EDGAR

Debt/Equity

Q2 2026

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/INVA

Earnings Per Share

13fpro.ai/company/INVA

Loading ratio trend…

Innoviva, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Op. marginOperating margin
FY 2025	10-K	$411.3M	$271.2M	39.8%
FY 2024	10-K	$358.7M	$23.4M	46.5%
FY 2023	10-K/A	$310.5M	$179.7M	36.7%
FY 2022	10-K/A	$331.3M	$220.3M	86.6%
FY 2021	10-K/A	$391.9M	$368.8M	95.7%
FY 2020	10-K/A	$336.8M	$293.8M	95.3%

About Innoviva, Inc. (INVA): stock profile, AI score and financials

Innoviva, Inc. (INVA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INVA at 70.9/100 on a composite quality score built from its SEC filings, placing it at rank #196 of 2,925 stocks — the top 10% of the AI-ranked universe. INVA scores in the top quartile across profitability (97.2), free cash flow (92.8), balance sheet strength (89.7). Areas of concern include institutional flow (25.0) and revenue scale (34.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 36.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Innoviva, Inc. reports quarterly revenue of $119.6M, net income of $-83.4M, an operating margin of 42.5%. Top institutional holders of INVA by reported 13-F value include BlackRock, DIMENSIONAL FUND ADVISORS, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. INVA trades on the Nasdaq exchange and files with the SEC under CIK 1080014. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INVA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Innoviva, Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1080014 →

Innoviva, Inc. INVA

Top Institutional Holders

What's Driving INVA's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Biggest Revenue Drivers

Largest Expense Items

Watch Items from the Filing

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

INVA key financials by period

INVA insiders

Congress trading in INVA

About Innoviva, Inc. (INVA): stock profile, AI score and financials

Innoviva, Inc. INVA

Top Institutional Holders

What's Driving INVA's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

INVA key financials by period

Companies similar to INVA

INVA insiders

Congress trading in INVA

About Innoviva, Inc. (INVA): stock profile, AI score and financials